Synflorix Injection

Active immunization for the prevention of pneumococcal disease, Meningitis, Sepsis, Bacteraemic pneumonia, Pleural empyema, Bacteraemia, Pneumococcal pneumonia

Not for adult

Intramuscular Active immunisation against pneumococcal disease Infant 6 wk-6 mth: 3-dose Primary series 1st dose given at 2 mth or at 6 wk of age, with 1-mth interval between doses. A booster dose is recommended at least 6 months after the last priming dose. 2-dose Primary series 2 doses w/ the 1st dose given at 2 mth of age, w/ 2-mth interval between 1st & 2nd dose. Infants 7-11 mth: 2 doses at least 1 mth apart, with the 3rd dose given in the 2nd yr of life. Infant & childn 12 mth-5 yr previously unvaccinated 2 doses w/ at least 2 mth interval between doses. Pre-term infant born at least 27 wk of gestation 3 doses w/ the 1st dose given at 2 mth of age, w/ 1-mth interval between doses. Booster dose Administer at least 6 mth after the last primary dose.

Hypersensitivity to any component of the vaccine. Febrile illness, acute disease, anaphylactic reaction to a previous dose, severe primary immunodeficiency.

Severe renal, hepatic, cardiac, vascular &/or pulmonary dysfunction. Patients on immunosuppressants may be unable to attain required antibody titres. Pregnancy & lactation. Efficacy may be reduced in multiple myeloma, Hodgkin's and non-Hogkin's lymphoma, especially during treatment and in chronic alcoholism. Vaccine should be given 2 wk before starting immunosuppressive treatment or at least 3 mth after treatment completion.

C Pregnancy Category: C Lactation: N/A

Adequate response may not be elicited w/ immunosuppressants.

Local inj site reactions, warmth, erythema & swelling; fever, headache, malaise.

These products convey active immunity via stimulation of production of endogenously produced antibodies .

Synflorix .5ml Injection manufactured by GlaxoSmithkline Biologicals S.A,Belgium. Its generic name is Pneumococcal Polysaccharide Conjugated Vaccine.